清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

A New Direction in Endometrial Cancer Therapy—PD-1 and PD-L1 Immune Checkpoint Inhibitors—Where Will It Take Us?

作者
Natalia Mielnicka,Martyna Dutka,Krzysztof Kułak,А. И. Кулак,Rafał Tarkowski
出处
期刊:Journal of Clinical Medicine [Multidisciplinary Digital Publishing Institute]
卷期号:14 (23): 8366-8366
标识
DOI:10.3390/jcm14238366
摘要

Background: Endometrial cancer (EC) remains a significant therapeutic challenge due to its rising incidence and a five-year survival rate of only 16% in cases of metastases or advanced disease when using classical therapy methods. For this reason, more effective methods of treatment are still sought, which currently focus on immunotherapy with the use of PD-1 and PD-L1 inhibitors (ICI), which is the subject of our article. Methods: Articles published in the databases: Pubmed, Web of Science, and ClinicalTrials.gov in the years 2019–2024 were analyzed. Results: ICIs can be used in monotherapy as well as in combination therapy, but it is the latter option that significantly prolongs the median PFS, especially the combination of ICI with PARP inhibitors. Among the available ICIs, pembrolizumab stands out with a large advantage in clinical trials, which is characterized by the lowest mortality resulting from therapy and a small number of grade 3 adverse events. Other inhibitors such as atezolizumab, dostarlimab, durvalumab, nivolumab and avelumab also demonstrate high clinical efficacy, as they prolong median PFS compared to the control group, but more studies are needed in much larger study groups to assess their safety and efficacy in different age groups. Conclusions: Future studies should focus on the efficacy of ICIs in younger groups of patients with EC, as well as on drugs from this group that are used less frequently in clinical trials than pembrolizumab, which would allow for a thorough comparison of the efficacy of drugs with each other and the selection of the drug individually to the patient’s needs.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
YZY完成签到 ,获得积分10
11秒前
自律完成签到,获得积分10
18秒前
kkk完成签到 ,获得积分10
19秒前
fans完成签到 ,获得积分10
23秒前
小草完成签到 ,获得积分10
27秒前
威武的迎蓉完成签到,获得积分10
28秒前
无私的迎蓉完成签到,获得积分10
35秒前
动听的山槐完成签到,获得积分10
42秒前
火柴盒完成签到,获得积分10
43秒前
CodeCraft的应助被武雨寒采纳,获得10
48秒前
ph完成签到 ,获得积分10
53秒前
cocolinfly完成签到 ,获得积分10
56秒前
武雨寒发布了新的文献求助10
1分钟前
虚心的手套完成签到,获得积分10
1分钟前
1分钟前
Virgil完成签到 ,获得积分10
1分钟前
小珂完成签到,获得积分10
1分钟前
脑洞疼的应助被帅气的熊猫采纳,获得10
1分钟前
1分钟前
哭泣青雪完成签到,获得积分10
1分钟前
1分钟前
1分钟前
Leo发布了新的文献求助10
1分钟前
气945发布了新的文献求助10
1分钟前
武雨寒发布了新的文献求助10
1分钟前
Leo完成签到,获得积分10
1分钟前
冷艳凡灵完成签到,获得积分10
1分钟前
cat发布了新的文献求助10
1分钟前
2分钟前
温柔的静丹完成签到,获得积分10
2分钟前
AAAAA发布了新的文献求助10
2分钟前
乐观的水瑶完成签到,获得积分10
2分钟前
2797924221完成签到,获得积分10
2分钟前
Imran完成签到,获得积分10
2分钟前
快乐的秋完成签到,获得积分10
2分钟前
2分钟前
冥土追魂发布了新的文献求助10
2分钟前
共享精神的应助被武雨寒采纳,获得10
2分钟前
明理傥完成签到,获得积分10
2分钟前
打打的应助被武雨寒采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166414
求助须知:如何正确求助?哪些是违规求助? 9559494
关于积分的说明 21750507
捐赠科研通 7757221
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553489
邀请新用户注册赠送积分活动 2473845